These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 29961337)
1. Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy. Liu S; Yang H; Jiang Y; Zhang T; Yan R; Zhang J Future Med Chem; 2018 Jul; 10(14):1705-1720. PubMed ID: 29961337 [TBL] [Abstract][Full Text] [Related]
5. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. Chin LP; Soo RA; Soong R; Ou SH J Thorac Oncol; 2012 Nov; 7(11):1625-30. PubMed ID: 23070242 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors. Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890 [TBL] [Abstract][Full Text] [Related]
7. ROS1 [corrected]. Pal P; Khan Z J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995 [TBL] [Abstract][Full Text] [Related]
8. Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors. Park BS; Al-Sanea MM; Abdelazem AZ; Park HM; Roh EJ; Park HM; Yoo KH; Sim T; Tae JS; Lee SH Bioorg Med Chem; 2014 Aug; 22(15):3871-8. PubMed ID: 24997577 [TBL] [Abstract][Full Text] [Related]
9. ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives. Guisier F; Piton N; Salaun M; Thiberville L Clin Lung Cancer; 2019 Nov; 20(6):e593-e596. PubMed ID: 31395437 [No Abstract] [Full Text] [Related]
10. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242 [TBL] [Abstract][Full Text] [Related]
11. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. Davies KD; Mahale S; Astling DP; Aisner DL; Le AT; Hinz TK; Vaishnavi A; Bunn PA; Heasley LE; Tan AC; Camidge DR; Varella-Garcia M; Doebele RC PLoS One; 2013; 8(12):e82236. PubMed ID: 24349229 [TBL] [Abstract][Full Text] [Related]
12. Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients. Juan O; Popat S Lung Cancer; 2017 Feb; 104():131-133. PubMed ID: 27863911 [No Abstract] [Full Text] [Related]
13. Crizotinib in the management of advanced-stage non-small-cell lung cancer. Loong HH; Mok K; Leung LK; Mok TS Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678 [TBL] [Abstract][Full Text] [Related]
14. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. Lu S; Azada MC; Ou SH Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789 [TBL] [Abstract][Full Text] [Related]
15. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations. Wu X; Wang Y; Wan S; Zhang J J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136 [TBL] [Abstract][Full Text] [Related]
16. [Crizotinib for ROS1-rearranged non-small cell lung cancer patients]. Domblides C; Antoine M; Lavole A; Cadranel J; Wislez M Bull Cancer; 2017 Apr; 104(4):303-310. PubMed ID: 28237354 [TBL] [Abstract][Full Text] [Related]
17. Structure-guided identification of potent inhibitors of ROS1 kinase for therapeutic development against non-small cell lung cancer. Khan MS; Altwaijry N; Al-Bagmi MS; Alafaleq NO; Alokail MS; Shahwan M; Shamsi A J Biomol Struct Dyn; 2024 May; 42(8):3837-3847. PubMed ID: 37254309 [TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502 [TBL] [Abstract][Full Text] [Related]
19. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. Yasuda H; de Figueiredo-Pontes LL; Kobayashi S; Costa DB J Thorac Oncol; 2012 Jul; 7(7):1086-90. PubMed ID: 22617245 [TBL] [Abstract][Full Text] [Related]
20. ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Ye M; Zhang X; Li N; Zhang Y; Jing P; Chang N; Wu J; Ren X; Zhang J Oncotarget; 2016 Mar; 7(11):12289-304. PubMed ID: 26802023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]